Key Highlights
- Jason Herod promoted to Chief Commercial Officer at Samsara Vision.
- Over 24 years of experience in the ophthalmic medical device industry.
- Will lead the global expansion of the SING IMT® for patients with late-stage AMD.
- SING IMT® device approved in 17 EU countries and under investigation in the U.S.
- Focus on market growth in China, APAC, Australia, and Latin America.
Source: Business Wire
Notable Quotes
- “His leadership contributed to our success earning a CE Mark and launching the SING IMT in 17 EU countries to date. I look forward to working with Jason even more closely as the Chief Commercial Officer as we build our business in China, APAC, Australia, and Latin America.” — Thomas Ruggia, President and CEO at Samsara Vision
- “I look forward to working with Tom and the rest of the Samsara Vision team to bring our remarkable technology to global markets around the world.” — Jason Herod, Chief Commercial Officer at Samsara Vision
SoHC's Take
The promotion of Jason Herod to Chief Commercial Officer at Samsara Vision underscores the company’s focus on strategic global expansion. His extensive background in ophthalmic devices and pharmaceuticals is invaluable as Samsara Vision seeks to broaden access to its groundbreaking SING IMT® technology. With the SING IMT already approved in 17 EU countries and under investigation in the U.S., Herod’s leadership will be instrumental in scaling the company’s success across new markets, particularly in Asia-Pacific and Latin America. This move positions Samsara Vision to further solidify its role as a leader in the ophthalmic device industry.
